Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors12
暂无分享,去创建一个
Paul D. Williams | Fiona Hyland | Paul Choppa | Rajesh Gottimukkala | Manimozhi Manivannan | Jeoffrey Schageman | Efren Ballesteros-Villagrana | Anmol Amin | Javed Siddiqui | Peter Wyngaard | Seth Sadis | Arul M Chinnaiyan | Paul D Williams | Daniel R Rhodes | A. Chinnaiyan | P. Nelson | R. Gottimukkala | D. Beer | K. Cooney | Guoying Liu | D. Rhodes | S. Tomlins | F. Feng | J. Siddiqui | K. Knudsen | J. Schageman | B. Betz | A. McDaniel | A. Cani | D. Hovelson | M. Quist | C. Grasso | P. Wyngaard | S. Sadis | M. Manivannan | Santhoshi Bandla | M. Roh | David G Beer | Kathleen A Cooney | Catherine S Grasso | Scott A Tomlins | Michael H Roh | Peter S Nelson | Felix Y Feng | Karen E Knudsen | Bryan L Betz | Bryan W. Johnson | Daniel H Hovelson | Guoying Liu | Kate Rhodes | Andrew S McDaniel | Andi K Cani | Bryan Johnson | Santhoshi Bandla | Geoffrey Bien | Michael J Quist | Venkata Yadati | Chia-Jen Liu | C. Liu | P. Choppa | A. Amin | V. Yadati | F. Hyland | Kate Rhodes | Geoffrey Bien | Efren Ballesteros-Villagrana
[1] J. Baselga,et al. Impact of Genomics on Personalized Cancer Medicine , 2012, Clinical Cancer Research.
[2] Andreas Heger,et al. Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy , 2014, European urology.
[3] Francesca Demichelis,et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma , 2010, Nature Medicine.
[4] M. Emi,et al. Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma , 1999, Genes, chromosomes & cancer.
[5] Edwin Cuppen,et al. Simultaneous detection of clinically relevant mutations and amplifications for routine cancer pathology. , 2015, The Journal of molecular diagnostics : JMD.
[6] Stephen J. Salipante,et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.
[7] S. Tomlins,et al. Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma , 2015, Virchows Archiv.
[8] S. Tomlins,et al. The prostate cancer genome: perspectives and potential. , 2014, Urologic oncology.
[9] Nickolay A. Khazanov,et al. 430 Analysis of 2,700 Cancer Exomes to Identify Novel Cancer Drivers and Therapeutic Opportunities , 2012 .
[10] Rashmi Kanagal-Shamanna,et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.
[11] Somasekar Seshagiri,et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. , 2006, Cancer research.
[12] Kathleen R. Cho,et al. HRAS mutations are frequent in inverted urothelial neoplasms. , 2014, Human pathology.
[13] P. Nelson,et al. The androgen/androgen receptor axis in prostate cancer , 2012, Current opinion in oncology.
[14] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[15] J. T. Jørgensen,et al. Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects , 2014, Front. Oncol..
[16] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[17] J. Mendelsohn. Personalizing oncology: perspectives and prospects. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Nelson,et al. Integrative molecular profiling of routine clinical prostate cancer specimens. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Arul M Chinnaiyan,et al. Common gene rearrangements in prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Rubin,et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. , 2013, European urology.
[21] S. Gabriel,et al. Pan-cancer patterns of somatic copy-number alteration , 2013, Nature Genetics.
[22] Michael R Stratton,et al. Genomics and the continuum of cancer care. , 2011, The New England journal of medicine.
[23] Russell Weiner,et al. Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics , 2014, Front. Oncol..
[24] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[25] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[26] Derek Y. Chiang,et al. Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.
[27] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[28] Stephen Moore,et al. Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. , 2015, The Journal of molecular diagnostics : JMD.
[29] Michael Ittmann,et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. , 2006, Cancer research.
[30] M. Rubin,et al. Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.
[31] Paul D. Williams,et al. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors , 2015, Molecular Cancer Research.
[32] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[33] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[34] A. Iafrate,et al. Anchored multiplex PCR for targeted next-generation sequencing , 2014, Nature Medicine.
[35] A. Eychène,et al. Alternative Splicing in Oncogenic Kinases: From Physiological Functions to Cancer , 2011, Journal of nucleic acids.
[36] C. Liang,et al. Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. , 2012, Endocrine-related cancer.
[37] B. Druker,et al. Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.
[38] Eric W. Klee,et al. Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma , 2014, PLoS genetics.
[39] S. Tomlins. Molecular Clues Assist in the Cancer Clinic , 2013, Science Translational Medicine.
[40] Jun Luo,et al. Decoding the androgen receptor splice variants , 2013, Translational andrology and urology.
[41] Dennis C. Friedrich,et al. Whole-exome sequencing and clinical interpretation of formalin-fixed , paraffin-embedded tumor samples to guide precision cancer medicine , 2014 .
[42] Ashish Choudhary,et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.
[43] J. Leamon,et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. , 2013, The Journal of molecular diagnostics : JMD.
[44] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[45] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[46] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .
[47] J. Trapman,et al. ETS fusion genes in prostate cancer. , 2014, Endocrine-related cancer.
[48] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[49] Levi A Garraway,et al. Precision oncology: an overview. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] J. Datta,et al. Comparison of custom capture for targeted next-generation DNA sequencing. , 2015, The Journal of molecular diagnostics : JMD.
[51] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[52] C. Vogel,et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. , 2005, Clinical breast cancer.
[53] Alex M. Fichtenholtz,et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing , 2013, Nature Biotechnology.
[54] David R Parkinson,et al. Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics , 2012, Clinical Cancer Research.
[55] M. Rubin,et al. New Strategies in Prostate Cancer: Translating Genomics into the Clinic , 2012, Clinical Cancer Research.
[56] T. Barrette,et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.